It especially affects patients with advanced HIV who have a cluster of differentiation 4 (CD4) count < 200 cells/mm3 or who are at stages III or IV of the World Health Organization (WHO) HIV infection clinical stages.1 In 2014, globally, the cryptococcal antigenaemia prevalence was estimated at 6% (278 000) amongst patients with CD4 < 100 cells/mm3, with approximately 223 100 cryptococcal meningitis cases occurring annually.2 In the same year, 2014, the annual deaths due to cryptococcal meningitis were estimated at 181 100, with 75% (135 900) of deaths occurring in sub-Saharan Africa.2 This evidence concerns the gene CD4 and HIV infectious disease.